Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 12, 2024, by Haleon Plc (LSE/NYSE: HLN), discloses transactions by Persons Discharging Managerial Responsibilities (PDMRs) in accordance with the UK Market Abuse Regulation. Haleon is a global consumer health leader with brands including Advil, Sensodyne, and Panadol.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive shareholding disclosures rather than financial performance.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific share acquisition events for two executives on November 11, 2024:
- Adrian Morris (General Counsel): Acquired 35 Partnership Shares at £3.6535 each and received 35 Matching Shares at no cost.
- Tamara Rogers (Chief Marketing Officer): Acquired 35 Partnership Shares at £3.6535 each and received 35 Matching Shares at no cost.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory notification of insider trading activity under the Company's Share Reward Plan.
Investor Verification Checklist
- Verify the total number of shares held by Adrian Morris and Tamara Rogers post-transaction.
- Confirm the terms of the Haleon Share Reward Plan regarding Matching Shares.
- Review the market price of Haleon ordinary shares on November 11, 2024, to contextualize the transaction price of £3.6535.